Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease.
Alzheimer's disease
NfL
biomarkers
blood biomarkers
clinical trials
dementia
fluid biomarkers
neurofilament light
plasma biomarkers
total tau
t‐tau
Journal
Alzheimer's & dementia (Amsterdam, Netherlands)
ISSN: 2352-8729
Titre abrégé: Alzheimers Dement (Amst)
Pays: United States
ID NLM: 101654604
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
06
2020
revised:
30
07
2020
accepted:
30
07
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL ( Plasma NfL is superior to t-tau in mild AD. The ability of NfL to detect changes before clinical manifestations makes it a promising biomarker of drug response in trials of disease-modifying drugs.
Identifiants
pubmed: 32995466
doi: 10.1002/dad2.12099
pii: DAD212099
pmc: PMC7507310
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12099Informations de copyright
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
Déclaration de conflit d'intérêts
Kaj Blennow has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Henrik Zetterberg has served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Niklas Mattsson‐Carlgren has no disclosures.
Références
Nat Med. 2019 Feb;25(2):277-283
pubmed: 30664784
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Arch Gen Psychiatry. 2012 Jan;69(1):98-106
pubmed: 22213792
JAMA. 2009 Dec 16;302(23):2557-64
pubmed: 20009055
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
pubmed: 9236950
JAMA Neurol. 2019 Jun 24;:
pubmed: 31233127
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Int J Geriatr Psychiatry. 2014 Jul;29(7):713-9
pubmed: 24318929
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Alzheimers Dement (Amst). 2018 Jul 02;10:448-451
pubmed: 30211292
Am J Neurodegener Dis. 2012;1(1):99-106
pubmed: 23383382
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Res Ther. 2013 Mar 28;5(2):9
pubmed: 23551972
Neurology. 2017 Nov 21;89(21):2167-2175
pubmed: 29070659
Neurology. 2017 Mar 7;88(10):930-937
pubmed: 28179466
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Brain. 2020 Apr 1;143(4):1220-1232
pubmed: 32206776
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
EBioMedicine. 2015 Nov 22;3:135-140
pubmed: 26870824
Neurology. 2016 Oct 25;87(17):1827-1835
pubmed: 27694257
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
Alzheimers Dement (Amst). 2019 Jun 28;11:483-492
pubmed: 31334328